Interim report January-June 2016: Good growth and broadened

Second quarter:

  · Sales amounted to SEK 208 (184) million, corresponding to an increase of 13
percent in SEK. Net sales growth was 15 percent in local currency.
  · Operating income before depreciation and amortisation (EBITDA) amounted to
SEK 74 (62) million, corresponding to a margin of 35 (34) percent.
  · Net income amounted to SEK 48 (39) million, which gave earnings per share of
SEK 2.21 (1.77).
  · Acquisition of all the shares in OCTAX and MTG, world-leaders in the field
of laser technology for IVF.
  · Vitrolife introduces EmbryoScope+ and broadens the time-lapse product
portfolio.

January-June:

  · Sales amounted to SEK 395 (347) million, corresponding to an increase of 14
percent in SEK. Net sales growth was 15 percent in local currency.
  · Operating income before depreciation and amortisation (EBITDA) amounted to
SEK 136 (116) million, corresponding to a margin of 34 (33) percent.
  · Net income amounted to SEK 87 (74) million, which gave earnings per share of
SEK 3.98 (3.38).

Gothenburg, July 15, 2016
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public
pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The
information was submitted for publication, through the agency of the contact
person set out above, at 8.30 am CET on July 15, 2016.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife is an international medical device Group. The Fertility product area
develops, produces and markets medical devices for assisted reproduction. Work
is also carried out to enable the use and handling of stem cells for therapeutic
purposes.

Vitrolife has about 360 employees and the company’s products are sold in about
110 markets. The company is headquartered in Gothenburg, Sweden, and there are
also offices in Australia, China, Denmark, France, Germany, Hungary, Italy,
Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ
Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Interim report January-June 2016: Good growth and broadened product portfolio

Attachments
